Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ARID1A is a coactivator of STAT5 that contributes to CD8+ T cell dysfunction and anti-PD-1 resistance in gastric cancer.

Pharmacological research - 1 Dec 2024

Ma Fangqi, Ren Mingming, Li Zhongqiu, Tang Yujing, Sun Xiaoyu, Wang Yi, Cao Nida, Zhu Xiaohong, Xu Yan, Wang Rui, Shen Yumiao, Zhao Ruohan, Li Zhaoyan, Ashrafizadeh Milad, Sethi Gautam, Wang Furong, Zhao Aiguang

Abstract excerpt

ARID1A deletion mutation contributes to improved treatment of several malignancies with immune checkpoint inhibitors (ICIs). However, its role in modulating of tumor immune microenvironment (TIME) of gastric cancer (GC) remains unclear. Here, we report an increase of CD8+ T cells infiltration in GC patients with ARID1A-mutation (MUT), which enhances sensitivity to ICIs. Kaplan-Meier survival analysis showed that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD8-Positive T-Lymphocytes
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Immune Checkpoint Inhibitors

Share to Programmed Cell Death 1 Receptor

Share to STAT5 Transcription Factor

Share to Stomach Neoplasms

Share to Tumor Microenvironment

Source

Identifiers

PMID: 39549895
DOI: 10.1016/j.phrs.2024.107499

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ARID1A is a coactivator of STAT5 that contributes to CD8+ T cell dysfunction and anti-PD-1 resistance in gastric cancer.PMID 39549895Read ↗

Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective studySemantic proximity Read ↗

Impaired ARID1A expression attenuated the immune response in gastric cancer via histone acetylation.Semantic proximity Read ↗

Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.Semantic proximity Read ↗

The effects of ARID1A mutation in gastric cancer and its significance for treatmentSemantic proximity Read ↗

Clinical outcome and molecular landscape of patients with ARID1A-loss gastric cancer.Semantic proximity Read ↗

Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities.Semantic proximity Read ↗

Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.Semantic proximity Read ↗

ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal CancerSemantic proximity Read ↗

Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancersSemantic proximity Read ↗

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.Semantic proximity Read ↗

Arid5a Promotes Immune Evasion by Augmenting Tryptophan Metabolism and Chemokine ExpressionSemantic proximity Read ↗

ARID1A Mutations in Gastric Cancer: A Review with Focus on Clinicopathological Features, Molecular Background and Diagnostic InterpretationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.